Literature DB >> 12361839

Proliferative activity in stenotic human aortocoronary bypass grafts.

Michael Hilker1, Gudrun Tellmann, Michael Buerke, Karin Gloger, Wolfgang Moersig, Helmut Oelert, Ulrich Hake, Hans-Anton Lehr.   

Abstract

BACKGROUND: Aortocoronary bypass graft disease is responsible for long-term failure of autologous vein grafts. The analyses of proliferation and cell type characterisation in human bypass grafts harvested during re-do surgery make it possible to investigate the cellular processes leading to bypass graft failure.
METHODS: 30 stenotic vein grafts and 25 control veins were explantated during re-do heart surgery procedures. The total area and cell count of the neointima, media and adventitia were calculated computer-assisted. Actively proliferating cells were identified using antibody to Ki-67 and positive cells were determined by double-label immunocytochemistry with SMC alpha-actin, CD 31 (endothelial cells), CD 68 (macrophages) and CD 45 (T-lymphocytes).
RESULTS: Active proliferation was detected in different cell types with an average proliferation index of 0.15%, 0.18% and 0.086% for neointima, media and adventitia. Only 9% of proliferating cells in the neointima were SMC (not identified cells 40%); correspondingly, 14% SMC (not identified cells 33%) were detected in the media. Endothelial cells turned out to be the predominant proliferating cell type in all sections of the vessel wall.
CONCLUSION: Proliferation in our series of stenotic vein grafts occurred at a low level, but was significantly higher compared to native control veins. While proliferation may play an important role in early lesions, our data clearly show low proliferation activity in advanced graft lesions. The identification of proliferating macrophages and T-lymphocytes implicate an additional inflammatory component in the development of human bypass graft disease.
SUMMARY: To clarify the role of cellular proliferation in human aortocoronary bypass grafts, we characterized the cellular composition and proliferation index in 30 stenotic saphenous vein grafts in comparison to 25 native veins. Proliferation in our series of stenotic vein grafts occurred at a low level, but was significantly higher compared to native control veins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361839     DOI: 10.1016/s1054-8807(02)00113-8

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  4 in total

1.  Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk.

Authors:  Helen E Chick; Ali Nowrouzi; Raffaele Fronza; Robert A McDonald; Nicole M Kane; Raul Alba; Christian Delles; William C Sessa; Manfred Schmidt; Adrian J Thrasher; Andrew H Baker
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

2.  A single nucleotide polymorphism of cyclin-dependent kinase inhibitor 1B (p27Kip1) associated with human vein graft failure affects growth of human venous adventitial cells but not smooth muscle cells.

Authors:  Richard D Kenagy; Shinsuke Kikuchi; Lihua Chen; Errol S Wijelath; Andrew B Stergachis; John Stamatoyannopoulos; Gale L Tang; Alexander W Clowes; Michael Sobel
Journal:  J Vasc Surg       Date:  2017-05-16       Impact factor: 4.268

3.  Antegrade cardioplegia as a possible cause of acute saphenous vein endothelial damage in patients undergoing on pump coronary artery bypass surgery.

Authors:  Ioannis Koukis; Stavros Siminelakis; Michalis Argiriou; Nikolaos Theakos; Anna Takou; George Pounis; Christos Charitos; Efstratios Apostolakis
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation.

Authors:  Yuhuang Li; Shuying Liu; Zhengyu Zhang; Qingbo Xu; Fukang Xie; Jingjing Wang; Suning Ping; Chen Li; Zhaojing Wang; Min Zhang; Jintao Huang; Dadi Chen; Liping Hu; Chaohong Li
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.